Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Probable serine protease inhibitor.. Additionally we are shipping Serine Peptidase Inhibitor, Kazal Type 7 (Putative) Antibodies (44) and Serine Peptidase Inhibitor, Kazal Type 7 (Putative) Proteins (7) and many more products for this protein.
Showing 4 out of 10 products:
Negative regulation of RNA-binding protein (show PTBP1 ELISA Kits) HuR (show ELAVL1 ELISA Kits) by tumor-suppressor ECRG2
ECRG2 in combination with cisplatin (DDP (show TIMM8A ELISA Kits)) can inhibit viability and induce apoptosis in esophageal cancer DDP (show TIMM8A ELISA Kits)-resistant cells, possibly via upregulation of p53 (show TP53 ELISA Kits) expression and downregulation of PCNA (show PCNA ELISA Kits) expression.
miR (show MLXIP ELISA Kits)-1322 can regulate ECRG2 in an allele-specific manner and that serum levels of miR (show MLXIP ELISA Kits)-1322 can serve as a potential diagnostic biomarker for patients with ESCC.
Conformational study of ECRG2 using NMR.
ECRG2 is a novel member of the Kazal-type serine protease inhibitor family and may function as a tumor suppressor gene regulating the protease cascades during carcinogenesis and invasion of esophageal cancer.
ECRG2 regulates invasion/migration partly through ECM (show MMRN1 ELISA Kits) degradation and uPA (show PRAP1 ELISA Kits)/uPAR (show PLAUR ELISA Kits)/FPRL1 (show FPR2 ELISA Kits) pathway
Data suggest that the physical interaction of esophageal cancer related gene 2 (ECRG2) and metallothionein 2A (MT2A (show MT2 ELISA Kits)) may play an important role in the carcinogenesis of esophageal cancer.
Potential interaction partner for ECRG2 might be involved in regulation of cell proliferation and apoptosis and in various physiological processes.
Short tandem repeat polymorphism in a novel esophageal cancer-related gene (ECRG2) implicates susceptibility to esophageal cancer
Short tandem repeat polymorphism TCA3/TCA3 (show CCL1 ELISA Kits) in exon 4 of ECRG2 is associated with poor relapse-free survival in surgically completely resected oral squamous cell carcinoma patients and might be a potential prognostic marker
Probable serine protease inhibitor.
, esophagus cancer-related gene 2 protein
, esophagus cancer-related protein 2
, serine peptidase inhibitor, Kazal type 7 (putative)
, serine protease inhibitor Kazal-type 7
, allergen Gal d 1
, allergen Gal d I
, esophagus cancer related gene 2
, esophagus cancer-related gene-2